Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALLO 715

Next Previous
Drug Profile

ALLO 715

Alternative Names: ALLO-715; Anti-BCMA AlloCAR T; Anti-BCMA CAR T cell therapy - Allogene; UCARTBCMA

Latest Information Update: 27 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectis
  • Developer Allogene Overland Biopharm; Allogene Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 27 May 2026 Allogene Therapeutics completes phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Monotherapy, Late-stage disease, In adults, In the elderly) in USA (Parenteral) (NCT04093596)
  • 01 Jul 2025 SpringWorks Therapeutics has been acquired by Merck KGaA
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top